| Analysis | Samples | Factors | Units |
|---|---|---|---|
| Normal phase NEGATIVE ION MODE | ATQ-20170130 | Drug:Atovaquone | Treatment conc.:10 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | ATQ-20170207 | Drug:Atovaquone | Treatment conc.:10 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | ATQ-20170224 | Drug:Atovaquone | Treatment conc.:10 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | ATQ-20170309 | Drug:Atovaquone | Treatment conc.:10 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | ATQ-20170316 | Drug:Atovaquone | Treatment conc.:10 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | ATQ-20170327 | Drug:Atovaquone | Treatment conc.:10 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | ATQ-20170413 | Drug:Atovaquone | Treatment conc.:10 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | ATQ-20170426 | Drug:Atovaquone | Treatment conc.:10 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | ATQ-20170802 | Drug:Atovaquone | Treatment conc.:10 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | ATQ-20170928 | Drug:Atovaquone | Treatment conc.:10 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | ATQ-20171019 | Drug:Atovaquone | Treatment conc.:10 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | MMV011772-20170928 | Drug:MMV011772 | Treatment conc.:6040 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | MMV1010248-20171019 | Drug:MMV1010248 | Treatment conc.:18795 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | MMV1068987-20171019 | Drug:MMV1068987 | Treatment conc.:7931.5 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | MMV1319550-20170207 | Drug:MMV1319550 | Treatment conc.:9680 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | MMV1319550-20170413 | Drug:MMV1319550 | Treatment conc.:9680 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | MMV1427995-20170130 | Drug:MMV1427995 | Treatment conc.:1389 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | MMV1427995-20170224 | Drug:MMV1427995 | Treatment conc.:1389 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | MMV1427995-20170413 | Drug:MMV1427995 | Treatment conc.:1389 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | MMV1431916-20170207 | Drug:MMV1431916 | Treatment conc.:6320 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | MMV1431916-20170426 | Drug:MMV1431916 | Treatment conc.:6320 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | MMV1432165-20170130 | Drug:MMV1432165 | Treatment conc.:1070 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | MMV1432165-20170224 | Drug:MMV1432165 | Treatment conc.:1070 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | MMV1432165-20170413 | Drug:MMV1432165 | Treatment conc.:1070 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | MMV1432711-20170802 | Drug:MMV1432711 | Treatment conc.:860 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | MMV1449124-20171019 | Drug:MMV1449124 | Treatment conc.:482.6 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | MMV1451822-20170207 | Drug:MMV1451822 | Treatment conc.:560 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | MMV1451822-20170327 | Drug:MMV1451822 | Treatment conc.:560 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | MMV1454442-20170130 | Drug:MMV1454442 | Treatment conc.:1730 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | MMV1454442-20170224 | Drug:MMV1454442 | Treatment conc.:1730 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | MMV1454442-20170413 | Drug:MMV1454442 | Treatment conc.:1730 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | MMV1490397-20170309 | Drug:MMV1490397 | Treatment conc.:1250 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | MMV1490397-20170426 | Drug:MMV1490397 | Treatment conc.:1250 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | MMV1490397-20171019 | Drug:MMV1490397 | Treatment conc.:1250 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | MMV1490405-20170309 | Drug:MMV1490405 | Treatment conc.:1130 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | MMV1490405-20170316 | Drug:MMV1490405 | Treatment conc.:1130 nM | Average Peak Area |
| Normal phase NEGATIVE ION MODE | ND-20170130 | Drug:None (Control) | Treatment conc.:N/A | Average Peak Area |
| Normal phase NEGATIVE ION MODE | ND-20170207 | Drug:None (Control) | Treatment conc.:N/A | Average Peak Area |
| Normal phase NEGATIVE ION MODE | ND-20170224 | Drug:None (Control) | Treatment conc.:N/A | Average Peak Area |
| Normal phase NEGATIVE ION MODE | ND-20170309 | Drug:None (Control) | Treatment conc.:N/A | Average Peak Area |
| Normal phase NEGATIVE ION MODE | ND-20170316 | Drug:None (Control) | Treatment conc.:N/A | Average Peak Area |
| Normal phase NEGATIVE ION MODE | ND-20170327 | Drug:None (Control) | Treatment conc.:N/A | Average Peak Area |
| Normal phase NEGATIVE ION MODE | ND-20170413 | Drug:None (Control) | Treatment conc.:N/A | Average Peak Area |
| Normal phase NEGATIVE ION MODE | ND-20170426 | Drug:None (Control) | Treatment conc.:N/A | Average Peak Area |
| Normal phase NEGATIVE ION MODE | ND-20170802 | Drug:None (Control) | Treatment conc.:N/A | Average Peak Area |
| Normal phase NEGATIVE ION MODE | ND-20170928 | Drug:None (Control) | Treatment conc.:N/A | Average Peak Area |
| Normal phase NEGATIVE ION MODE | ND-20171019 | Drug:None (Control) | Treatment conc.:N/A | Average Peak Area |
Return to study ST001074 main page
Download data matrix(Open source discovery of starting points for next generation chemoprotective antimalarial drugs (Biofocus 1) Normal phase NEGATIVE ION MODE)
- Metabolomics Workbench
|